What does InBrain Pharma do?
InBrain Pharma specializes in developing therapeutic solutions for neurodegenerative diseases by leveraging personalized medicine. The company focuses on titrating dopamine in the brain through a circadian intracerebroventricular infusion approach, specifically targeting advanced-stage Parkinson’s disease.
How much did they raise?
The company raised €1.8M in funding from undisclosed backers, in a round not classified under a specific series.
What are their plans for the money?
The funds will be used to support the PERCEPAR project, a novel therapeutic innovation aimed at improving treatment options for Parkinson’s patients. This investment is expected to drive significant advancements in neurodegenerative treatment methods.
What have they achieved so far?
InBrain Pharma has already made notable progress by securing a global license from SATT Nord to exploit the patents for its therapeutic approach, which is based on extensive research conducted at the University of Lille and Lille University Hospital.
